Quotes 5-day view Delayed Nyse
03/01/2021
03/02/2021
03/03/2021
03/04/2021
03/05/2021
Date
108.41(c)
107.85(c)
106.71(c)
105.65(c)
106.7(c)
Last
4 710 324
5 487 024
7 218 708
7 503 733
7 181 268
Volume
+0.62% -0.52% -1.06% -0.99% +0.99% Change
Sales 2021
55 324 M - -
Net income 2021
15 392 M - -
Net Debt 2021
65 947 M - -
P/E ratio 2021
13,1x
Yield 2021
4,81%
Sales 2022
58 757 M - -
Net income 2022
17 207 M - -
Net Debt 2022
52 077 M - -
P/E ratio 2022
11,3x
Yield 2022
5,15%
Capitalization
188 B 188 B -
EV / Sales 2021
4,60x
EV / Sales 2022
4,09x
Nbr of Employees
47 000
Free-Float
98,4%
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (76.1%), Japan (2.6%),...
Notations Surperformance© of AbbVie Inc.
Trading Rating : Investor Rating :
All news about ABBVIE INC.
News in other languages on ABBVIE INC.
Analyst Recommendations on ABBVIE INC.
Berkshire's bet a bright spot in gloomy year for Big Pharma stocks
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ABBVIE INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
24
Average target price
119,67 $
Last Close Price
106,70 $
Spread / Highest target
31,2%
Spread / Average Target
12,2%
Spread / Lowest Target
-9,09%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
